Reading CRNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRNX free→Reading CRNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRNX free→QuarterlyIQ Insights · CRNX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended March 31, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “f…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported on the Current Report on Form 8-K filed by Crinetics Pharmaceuticals, Inc. (the “Company”) on March 23, 2026, Jeff Knight notified the Company of his decision to resign as Chief Development and Operating Officer of the Company, effective April 10, 2026 (the “Resignation Date”). On April 10, 2026, the Company entered into an I…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Jeff Knight notified Crinetics Pharmaceuticals, Inc. (the “Company”) of his decision to resign as Chief Development and Operating Officer of the Company, effective on or about April 10, 2026. Mr. Knight resigned to pursue another opportunity, and his resignation is not related to any disagreement with the Company on any matter re…
Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of Crinetics Pharmaceuticals, Inc. (the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company’s independent registered public accounting firm. The reports of BDO on the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not…
Results of Operations and Financial Condition. On February 26, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended December 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 20, 2026, the board of directors of Crinetics Pharmaceuticals, Inc. (the “Company”) approved a change in title and responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, 2026. The change in title reflects Mr. Knight's responsibilities and scope of duties. There were…
Results of Operations and Financial Condition. On January 13, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) reiterated certain previously announced preliminary and unaudited financial and operating results for the fourth quarter ended December 31, 2025, including that Crinetics expects to report that it generated net product revenue from PALSONIFY TM (paltusotine) of over $5.0 million for the three months ended December 31, 2025. Crinetics’ audited financial statements…
Other Events. On January 6, 2026, Crinetics Pharmaceuticals, Inc. (“Crinetics” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 7,620,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, under the terms of the Under…
Results of Operations and Financial Condition. On January 5, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced certain preliminary and unaudited financial and operating results for the fourth quarter ended December 31, 2025, including that Crinetics expects to report that it generated net product revenue from PALSONIFY TM (paltusotine) of over $5.0 million for the three months ended December 31, 2025. Crinetics’ audited financial statements for the year ended Dece…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 16, 2025, Crinetics Pharmaceuticals, Inc. (the “Company”) and Dana Pizzuti, M.D. determined that Dr. Pizzuti will step down from her position as Chief Medical and Development Officer of the Company effective December 31, 2025. On the terms set forth in the Transition Agreement (as defined below), Dr. Pizzuti will continue her employment…
Results of Operations and Financial Condition. On November 6, 2025 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be…
Other Events. On September 25, 2025, the FDA approved PALSONIFY for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (“SST2”) agonist, is now the first once-daily, oral treatment approved for adults with acromegaly. This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities A…
Regulation FD Disclosure. On September 25, 2025, Crinetics Pharmaceuticals, Inc. (the “Company,” “Crinetics,” “we,” “us,” or “our”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) approved PALSONIFY TM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (“SST2”) agonist, is now the fi…
Results of Operations and Financial Condition. On August 7, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “…
Results of Operations and Financial Condition. On May 8, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “fi…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported on the Current Reports on Form 8-K filed by Crinetics Pharmaceuticals, Inc. (the “Company”) on August 8, 2024 and February 24, 2025, Marc Wilson ceased serving as the Chief Financial Officer of the Company, effective February 28, 2025, after which he remained with the Company as an employee to assist with the transition of hi…
Results of Operations and Financial Condition. On February 27, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended December 31, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be d…
Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Mr. Schilke On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025. Mr. Schilke, 50, is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In p…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.